PriceTargets.com logo

Blueprint Medicines - BPMC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $122.11
  • Forecasted Upside: 35.46%
  • Number of Analysts: 21
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 12 Buy Ratings
  • 2 Strong Buy Ratings
$90.14 As of 12/20/2024 06:31 PM ET
▲ +1.21 (1.36%)

This chart shows the closing price for BPMC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

Analyst Price Target is $122.11
▲ +35.46% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $122.11, with a high forecast of $168.00 and a low forecast of $76.00. The average price target represents a 35.46% upside from the last price of $90.14.

This chart shows the closing price for BPMC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 21 polled investment analysts is to moderate buy stock in Blueprint Medicines. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
9/27/2023
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 2 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024GuggenheimReiterated RatingBuy ➝ Buy
12/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00
11/18/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00
11/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
11/14/2024WedbushReiterated RatingOutperform$135.00
11/14/2024JPMorgan Chase & Co.Initiated CoverageOverweight$126.00
10/31/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$153.00 ➝ $151.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
10/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$133.00 ➝ $133.00
10/24/2024UBS GroupInitiated CoverageNeutral$88.00
8/2/2024Baird R WUpgradeStrong-Buy
8/2/2024GuggenheimBoost TargetBuy ➝ Buy$130.00 ➝ $138.00
8/2/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$112.00 ➝ $127.00
8/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
7/29/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$75.00 ➝ $105.00
7/12/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $115.00
7/8/2024OppenheimerBoost TargetOutperform ➝ Outperform$114.00 ➝ $125.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
6/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00
5/14/2024StephensInitiated CoverageOverweight$140.00
5/6/2024Leerink PartnrsUpgradeUnderperform ➝ Market Perform
5/6/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$121.00 ➝ $168.00
5/6/2024Leerink PartnersUpgradeUnderperform ➝ Market Perform$50.00 ➝ $97.00
5/3/2024CitigroupBoost TargetSell ➝ Sell$65.00 ➝ $76.00
5/3/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$114.00 ➝ $125.00
5/3/2024HC WainwrightBoost TargetBuy ➝ Buy$125.00 ➝ $135.00
5/3/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$70.00 ➝ $75.00
5/3/2024Piper SandlerBoost TargetNeutral ➝ Neutral$78.00 ➝ $104.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$97.00 ➝ $97.00
4/26/2024Stifel NicolausBoost TargetBuy ➝ Buy$120.00 ➝ $130.00
4/26/2024WedbushReiterated RatingOutperform ➝ Outperform$110.00 ➝ $110.00
4/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$97.00
4/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$125.00
4/10/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$114.00
2/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$97.00
2/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$114.00
2/16/2024CitigroupBoost TargetSell ➝ Sell$54.00 ➝ $65.00
2/13/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$58.00 ➝ $70.00
2/5/2024WedbushReiterated RatingOutperform$97.00
1/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$114.00
1/9/2024Stifel NicolausBoost TargetBuy ➝ Buy$95.00 ➝ $97.00
1/8/2024WedbushReiterated RatingOutperform$100.00 ➝ $97.00
12/22/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$85.00 ➝ $100.00
12/19/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$86.00 ➝ $115.00
12/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$85.00
11/10/2023WedbushReiterated RatingOutperform$80.00
10/27/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$59.00 ➝ $63.00
10/27/2023OppenheimerUpgradeMarket Perform ➝ Outperform$85.00
10/27/2023Needham & Company LLCBoost TargetBuy ➝ Buy$66.00 ➝ $74.00
10/27/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$46.00 ➝ $58.00
8/21/2023Needham & Company LLCBoost TargetBuy ➝ Buy$65.00 ➝ $66.00
8/7/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$114.00
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$55.00 ➝ $59.00
8/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$93.00 ➝ $83.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$85.00
8/2/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$65.00
7/31/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$55.00 ➝ $82.00
7/14/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$55.00
6/14/2023Wells Fargo & CompanyBoost Target$48.00 ➝ $55.00
6/5/2023Leerink PartnersDowngradeMarket Perform ➝ Underperform
6/5/2023SVB SecuritiesDowngradeMarket Perform ➝ Underperform$48.00 ➝ $43.00
5/23/2023GuggenheimBoost Target$78.00 ➝ $82.00
5/23/2023HC WainwrightBoost Target$75.00 ➝ $85.00
5/23/2023BarclaysBoost Target$44.00 ➝ $46.00
5/5/2023VNET GroupReiterated RatingMaintains
5/5/2023HC WainwrightBoost Target$70.00 ➝ $75.00
4/19/2023Needham & Company LLCReiterated RatingBuy$57.00
3/30/2023JMP SecuritiesReiterated RatingMarket Outperform$114.00
3/21/2023Stifel NicolausBoost Target$80.00 ➝ $84.00
2/28/2023JMP SecuritiesReiterated RatingMarket Perform$114.00
2/28/2023HC WainwrightReiterated RatingBuy$70.00
2/28/2023Needham & Company LLCReiterated RatingBuy$57.00
2/24/2023SVB SecuritiesLower Target$45.00 ➝ $38.00
2/24/2023Leerink PartnersLower TargetMarket Perform$45.00 ➝ $38.00
2/17/2023Needham & Company LLCLower TargetBuy$60.00 ➝ $57.00
2/17/2023HC WainwrightReiterated RatingBuy$70.00
2/17/2023Raymond JamesLower TargetStrong-Buy$115.00 ➝ $85.00
2/10/2023Needham & Company LLCReiterated RatingBuy$60.00
1/27/2023Morgan StanleyLower TargetEqual Weight$75.00 ➝ $50.00
1/23/2023BarclaysLower TargetEqual Weight$50.00 ➝ $44.00
1/2/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$41.00
12/14/2022Needham & Company LLCInitiated CoverageBuy$60.00
12/12/2022BarclaysLower TargetEqual Weight$58.00 ➝ $53.00
11/4/2022JMP SecuritiesLower TargetMarket Outperform$152.00 ➝ $114.00
11/3/2022The Goldman Sachs GroupLower TargetBuy$143.00 ➝ $108.00
11/2/2022Jefferies Financial GroupLower Target$84.00 ➝ $80.00
11/2/2022Leerink PartnersLower TargetMarket Perform$57.00 ➝ $52.00
11/2/2022Morgan StanleyLower TargetEqual Weight$80.00 ➝ $75.00
11/2/2022BarclaysLower TargetEqual Weight$70.00 ➝ $58.00
11/2/2022WedbushLower TargetOutperform$120.00 ➝ $106.00
11/2/2022HC WainwrightLower TargetBuy$80.00 ➝ $70.00
11/2/2022OppenheimerDowngradeOutperform ➝ Market Perform
9/14/2022Berenberg BankInitiated CoverageBuy$90.00
9/9/2022Morgan StanleyBoost TargetEqual Weight$65.00 ➝ $80.00
9/7/2022Credit Suisse GroupBoost Target$80.00 ➝ $90.00
9/6/2022OppenheimerBoost TargetOutperform$80.00 ➝ $90.00
8/22/2022Jefferies Financial GroupBoost TargetBuy$78.00 ➝ $84.00
8/18/2022Leerink PartnersLower TargetMarket Perform ➝ Market Perform$65.00 ➝ $57.00
8/18/2022Stifel NicolausBoost TargetBuy$93.00 ➝ $100.00
8/17/2022HC WainwrightLower TargetBuy$100.00 ➝ $80.00
8/3/2022Raymond JamesLower TargetStrong-Buy$133.00 ➝ $115.00
8/3/2022HC WainwrightReiterated RatingBuy
8/3/2022The Goldman Sachs GroupBoost TargetBuy$126.00 ➝ $143.00
8/3/2022Leerink PartnersBoost TargetMarket Perform$56.00 ➝ $65.00
8/2/2022Piper SandlerLower Target$65.00 ➝ $59.00
7/7/2022OppenheimerInitiated CoverageOutperform$80.00
7/1/2022Stifel NicolausLower Target$98.00 ➝ $90.00
7/1/2022Leerink PartnersLower TargetMarket Perform$60.00 ➝ $56.00
6/27/2022Wells Fargo & CompanyInitiated CoverageUnderweight$40.00
6/14/2022Morgan StanleyLower TargetEqual Weight$92.00 ➝ $65.00
6/13/2022Leerink PartnersLower TargetMarket Perform$82.00 ➝ $60.00
6/10/2022HC WainwrightReiterated RatingBuy$100.00
6/9/2022CitigroupDowngradeNeutral ➝ Sell$68.00 ➝ $41.00
6/9/2022JMP SecuritiesReiterated RatingBuy$152.00
6/1/2022Jefferies Financial GroupUpgradeHold ➝ Buy$88.00 ➝ $78.00
5/18/2022Piper SandlerLower TargetNeutral$84.00 ➝ $65.00
5/4/2022Robert W. BairdLower Target$123.00 ➝ $96.00
4/13/2022CitigroupLower TargetNeutral$71.00 ➝ $68.00
4/11/2022JMP SecuritiesReiterated RatingBuy$152.00
3/4/2022Stifel NicolausBoost TargetBuy$100.00 ➝ $105.00
2/28/2022WedbushReiterated RatingOutperform$126.00
2/28/2022CitigroupInitiated CoverageNeutral$71.00
2/17/2022Leerink PartnersLower TargetOutperform ➝ Market Perform$93.00 ➝ $82.00
2/17/2022HC WainwrightLower TargetBuy$135.00 ➝ $100.00
2/1/2022Morgan StanleyLower TargetEqual Weight$111.00 ➝ $92.00
1/24/2022Stifel NicolausUpgradeHold ➝ Buy$120.00 ➝ $95.00
1/12/2022Leerink PartnersLower TargetOutperform$132.00 ➝ $120.00
1/3/2022GuggenheimBoost Target$120.00 ➝ $122.00
11/30/2021HC WainwrightReiterated RatingBuy$134.00
11/30/2021JMP SecuritiesReiterated RatingBuy$151.00
11/10/2021Raymond JamesBoost TargetStrong-Buy$122.00 ➝ $133.00
10/29/2021Morgan StanleyBoost TargetEqual Weight$96.00 ➝ $111.00
7/30/2021Morgan StanleyLower TargetEqual Weight$101.00 ➝ $96.00
6/17/2021WedbushLower TargetOutperform$136.00 ➝ $130.00
6/17/2021Leerink PartnersBoost TargetOutperform$127.00 ➝ $137.00
6/17/2021Robert W. BairdBoost TargetOutperform$119.00 ➝ $123.00
4/30/2021Morgan StanleyLower TargetEqual Weight$105.00 ➝ $101.00
4/13/2021WedbushBoost TargetOutperform$119.00 ➝ $136.00
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$100.00
2/25/2021Morgan StanleyLower TargetEqual Weight$112.00 ➝ $105.00
2/18/2021HC WainwrightReiterated RatingBuy
2/18/2021BarclaysBoost TargetEqual Weight$90.00 ➝ $95.00
1/12/2021Leerink PartnersBoost TargetPositive ➝ Outperform$121.00 ➝ $127.00
12/18/2020JMP SecuritiesBoost TargetOutperform$118.00 ➝ $152.00
12/14/2020BMO Capital MarketsBoost TargetOutperform$113.00 ➝ $132.00
12/2/2020Stifel NicolausInitiated CoverageHold$110.00
11/2/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $96.00
11/2/2020HC WainwrightBoost TargetBuy$110.00 ➝ $135.00
10/30/2020WedbushBoost Target$102.00 ➝ $115.00
10/30/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00
10/29/2020Piper SandlerBoost TargetNeutral$77.00 ➝ $81.00
10/16/2020Raymond JamesBoost TargetPositive ➝ Strong-Buy$106.00 ➝ $122.00
10/13/2020Morgan StanleyBoost TargetOverweight$92.00 ➝ $100.00
9/23/2020Leerink PartnersBoost TargetOutperform$107.00 ➝ $121.00
9/23/2020BMO Capital MarketsBoost TargetOutperform$105.00 ➝ $113.00
9/23/2020BarclaysBoost TargetEqual Weight$77.00 ➝ $90.00
9/22/2020Raymond JamesReiterated RatingBuy
9/2/2020Raymond JamesReiterated RatingBuy
7/31/2020HC WainwrightReiterated RatingBuy
7/27/2020Leerink PartnersBoost TargetOutperform$106.00 ➝ $107.00
7/15/2020Morgan StanleyBoost TargetOverweight$88.00 ➝ $92.00
7/15/2020BarclaysReiterated RatingHold ➝ Neutral
7/15/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$85.00 ➝ $95.00
7/15/2020Leerink PartnersBoost TargetOutperform$105.00 ➝ $106.00
7/15/2020HC WainwrightBoost TargetBuy$66.00 ➝ $110.00
7/14/2020Robert W. BairdBoost TargetOutperform$90.00 ➝ $100.00
7/14/2020Raymond JamesBoost TargetPositive ➝ Strong-Buy$95.00 ➝ $106.00
6/8/2020Deutsche Bank AktiengesellschaftBoost TargetPositive ➝ Buy$70.00 ➝ $85.00
6/8/2020BMO Capital MarketsBoost TargetOutperform$75.00 ➝ $111.00
5/7/2020HC WainwrightReiterated RatingBuy$66.00
5/4/2020BarclaysInitiated CoverageEqual Weight$59.00
4/30/2020Morgan StanleyLower TargetOverweight$103.00 ➝ $88.00
4/29/2020JMP SecuritiesLower TargetMarket Outperform$107.00 ➝ $103.00
4/29/2020BMO Capital MarketsLower TargetOutperform$89.00 ➝ $75.00
4/29/2020Leerink PartnersLower TargetOutperform$125.00 ➝ $105.00
4/29/2020HC WainwrightLower TargetBuy$100.00 ➝ $66.00
3/24/2020WedbushReiterated RatingOutperform
3/17/2020Leerink PartnersBoost TargetOutperform ➝ Positive$116.00 ➝ $125.00
3/17/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$74.00 ➝ $89.00
3/16/2020CowenInitiated CoverageBuy
3/16/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$70.00
2/18/2020Morgan StanleyLower TargetOverweight$108.00 ➝ $103.00
2/13/2020CowenReiterated RatingBuy
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$74.00
1/15/2020WedbushReiterated RatingPositive ➝ Outperform$141.00 ➝ $122.00
1/10/2020Leerink PartnersBoost Target$103.00 ➝ $120.00
1/9/2020HC WainwrightReiterated RatingBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.43 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 14 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 13 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 16 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/22/2024
  • 14 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 24 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 39 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 39 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $90.14
Low: $87.99
High: $90.99

50 Day Range

MA: $92.45
Low: $82.47
High: $101.39

52 Week Range

Now: $90.14
Low: $72.24
High: $121.90

Volume

1,267,436 shs

Average Volume

690,807 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?

The following Wall Street analysts have issued stock ratings on Blueprint Medicines in the last year: Baird R W, Barclays PLC, Citigroup Inc., Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Stephens, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BPMC.

What is the current price target for Blueprint Medicines?

0 Wall Street analysts have set twelve-month price targets for Blueprint Medicines in the last year. Their average twelve-month price target is $122.11, suggesting a possible upside of 35.5%. The Goldman Sachs Group, Inc. has the highest price target set, predicting BPMC will reach $168.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $76.00 for Blueprint Medicines in the next year.
View the latest price targets for BPMC.

What is the current consensus analyst rating for Blueprint Medicines?

Blueprint Medicines currently has 1 sell rating, 6 hold ratings, 12 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BPMC.

What other companies compete with Blueprint Medicines?

Other companies that are similar to Blueprint Medicines include Teva Pharmaceutical Industries, BeiGene, Moderna, Viatris and Summit Therapeutics. Learn More about companies similar to Blueprint Medicines.

How do I contact Blueprint Medicines' investor relations team?

Blueprint Medicines' physical mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 374-7580 and its investor relations email address is [email protected]. The official website for Blueprint Medicines is www.blueprintmedicines.com. Learn More about contacing Blueprint Medicines investor relations.